Scalper1 News
Drugmaker stocks were on the move Monday as the American Society of Clinical Oncology (ASCO) meeting continued to produce key data on cancer trials. Among the top movers were: ImmunoGen (IMGN) stock soared as much as 71% to a 13-month high above 15 based on its Saturday report on its phase-one trial of mirvetuximab soravtansine, or IMGN853, in ovarian cancer. The objective response rate — the percentage of tumors that shrank — was 53%, which Scalper1 News
Scalper1 News